Skip to main content

Table 5 Risk factors for CLL

From: Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?

VariablesUnivariateMultivariate
OR95% CIpOR95% CIp
Gender
 Femaleref     
 Male3.131.27–7.670.013*   
WBC1.611.29–2.00< 0.001*1.581.26–2.01< 0.001*
Neutrophil1.130.93–1.370.229   
Platelet0.980.97–0.980.026*   
ELABELA1.311.13–1.52< 0.001*1.381.17–1.63< 0.001*
    Nagelkerke R2 = 0.849; p < 0.001*
  1. Abbreviations: OR Odds ratio, CI Confidence intervals
  2. * P < 0.05 indicates statistical significance